gp100 Melanoma Antigen

• 

  Subject Areas on Research

  • Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. 
  • Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3. 
  • Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. 
  • Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. 
  • Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. 
  • Functional heterogeneity of vaccine-induced CD8(+) T cells. 
  • Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. 
  • Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity. 
  • Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. 
  • Kinetics of TCR use in response to repeated epitope-specific immunization. 
  • Laser scanning cytometry evaluation of MART-1, gp100, and HLA-A2 expression in melanoma metastases. 
  • Long-term survival of anti-tumor lymphocytes generated by vaccination of patients with melanoma with a peptide vaccine. 
  • Melanoma, a tumor based on a mutant stem cell? 
  • Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity. 
  • Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. 
  • Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. 
  • Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. 
  • Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100. 
  • Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites.